{"contentid": 488478, "importid": NaN, "name": "Enzyvant resubmits BLA for pediatric congenital athymia drug", "introduction": "Nearly 18 months on from Enzyvant\u00e2\u0080\u0099s receipt of a Complete Response Letter (CRL) relating to its initial Biologics Licensing Application (BLA) for RVT-802, the company has filed an amended submission.", "content": "<p>Nearly 18 months on from Enzyvant&rsquo;s receipt of a Complete Response Letter (CRL) relating to its initial Biologics Licensing Application (BLA) for RVT-802, the company has filed an amended submission.</p>\n<p>The US Food and Drug Administration (FDA) made several regulatory requests related to chemistry, manufacturing and controls in a December 2019 CRL that followed the first RVT-802 BLA submission in April 2019.</p>\n<p>Enzyvant has been working since that time to address each of the FDA requests. The expected action date provided by the agency under the Prescription Drug User Fee Act is October 8, 2021.</p>\n<p>An ultra-rare condition in which children are born without a thymus, congenital athymia can lead to profound immunodeficiency, immune dysregulation and high susceptibility to infections.</p>\n<p>With only supportive care, patients with congenital athymia typically die from infections or autoimmune manifestations by age two or three. Currently, there are no FDA-approved treatments available for congenital athymia.</p>\n<p>RVT802 has been granted multiple regulatory designations, including the FDA classification as a Regenerative Medicine Advanced Therapy.</p>\n<p>Rachelle Jacques is chief executive of Enzyvant, which is part of Sumitovant Biopharma, the subsidiary of Sumitomo Dainippon Pharma (TYO: 4506).</p>\n<p>She said: &ldquo;Resubmission of the RVT-802 BLA is important progress in the mission to bring a desperately needed treatment option to families battling the dire consequences of congenital athymia.</p>\n<p>&ldquo;Thank you to everyone involved in the RVT-802 development program, including families who participated in clinical trials, for your efforts to achieve this milestone and make a difference in the lives of families who will face this condition in the future.&rdquo;</p>", "date": "2021-04-28 11:39:00", "meta_title": NaN, "meta_keywords": "congenital, athymia, RVT-, drug, Enzyvant, submission, pediatric, resubmits, Letter, relating, receipt, Response, Complete, months, amended, filed, company", "meta_description": "Nearly 18 months on from Enzyvant\u00e2\u0080\u0099s receipt of a Complete Response Letter (CRL) relating to its initial Biologics Licensing Application (BLA) for RVT-802, the c", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-28 11:36:50", "updated": "2021-04-28 12:38:44", "access": NaN, "url": "https://www.thepharmaletter.com/article/enzyvant-resubmits-bla-for-pediatric-congenital-athymia-drug", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "enzyvant_large.png", "image2id": "enzyvant_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immunologicals, Rare diseases", "topic_tag": "Focus On, Legal, Regulation", "geography_tag": "Japan, USA", "company_tag": "Enzyvant Sciences", "drug_tag": "RVT-802", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-28 11:39:00"}